What Uniqure NV's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 35 | 64 |
| Total trades | 55 | 101 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 101 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director | Jul 02 | Disclosed 10b5-1 sale · S | −7,600 | $45.89 | −$349K | 519,227 |
| Kapusta Matthew C | CEO, Managing Director | Jul 02 | Disclosed 10b5-1 sale · S | −4,282 | $45.43 | −$195K | 526,827 |
| Kapusta Matthew C | CEO, Managing Director | Jul 02 | Disclosed 10b5-1 sale · S | −9,200 | $44.43 | −$409K | 531,109 |
| Kapusta Matthew C | CEO, Managing Director | Jul 02 | Exercise / conversion · M | +21,082 | $19.39 | +$409K | 540,309 |
| Kaye Jack | Director | Jun 30 | Disclosed 10b5-1 sale · S | −17,060 | $46.43 | −$792K | 25,996 |
| Kaye Jack | Director | Jun 30 | Exercise / conversion · M | +17,060 | $20.18 | +$344K | 43,056 |
| Kaye Jack | Director | Jun 30 | Disclosed 10b5-1 sale · S | −4,107 | $46.49 | −$191K | 25,996 |
| Kaye Jack | Director | Jun 30 | Exercise / conversion · M | +4,107 | $37.00 | +$152K | 30,103 |
| Abi-Saab Walid | Chief Medical Officer | Jun 30 | Disclosed 10b5-1 sale · S | −20,000 | $46.40 | −$928K | 148,235 |
| Abi-Saab Walid | Chief Medical Officer | Jun 30 | Disclosed 10b5-1 sale · S | −10,000 | $46.46 | −$465K | 168,235 |
| Abi-Saab Walid | Chief Medical Officer | Jun 30 | Exercise / conversion · M | +10,000 | $5.59 | +$55.9K | 178,235 |
| Abi-Saab Walid | Chief Medical Officer | Jun 26 | Sale for tax withholding · S | −1,434 | $46.86 | −$67.2K | 168,235 |
| Kapusta Matthew C | CEO, Managing Director | Jun 25 | Disclosed 10b5-1 sale · S | −28,716 | $50.02 | −$1.44M | 519,227 |
| Kapusta Matthew C | CEO, Managing Director | Jun 25 | Exercise / conversion · M | +28,716 | $31.71 | +$911K | 547,943 |
| Kapusta Matthew C | CEO, Managing Director | Jun 24 | Disclosed 10b5-1 sale · S | −6,696 | $50.00 | −$335K | 519,227 |
| Kapusta Matthew C | CEO, Managing Director | Jun 24 | Exercise / conversion · M | +4,128 | $31.71 | +$131K | 525,923 |
| Kapusta Matthew C | CEO, Managing Director | Jun 18 | Disclosed 10b5-1 sale · S | −37,015 | $50.00 | −$1.85M | 521,795 |
| Kapusta Matthew C | CEO, Managing Director | Jun 18 | Disclosed 10b5-1 sale · S | −4,656 | $50.00 | −$233K | 558,810 |
| Kapusta Matthew C | CEO, Managing Director | Jun 18 | Exercise / conversion · M | +4,656 | $31.71 | +$148K | 563,466 |
| Kaye Jack | Director | Jun 17 | Disclosed 10b5-1 sale · S | −5,295 | $42.57 | −$225K | 25,996 |
Loading...